APPENDIX 4E
Preliminary Final Report to the Australian Stock Exchange

Name of Entity	Paradigm Biopharmaceuticals Limited
ABN	(ABN 94 169 346 963)
Year Ended	30 June 2015
Previous Corresponding Reporting Period	02 May 2014 to 30 June 2014

1. Results for Announcement to the Market

	$	**$ and % increase/(decrease) over previous corresponding period**
Revenue from continuing activities	7,331	7,331 100%
(Loss) from continuing activities after tax attributable to members	(1,081,105)	1,042,532 2,702.75%
Net (loss) for the period attributable to members	(1,081,105)	1,042,532 2,702.75%

Dividends (distributions)	**Amount per security**	**Franked amount per security**
Final Dividend	N/A	N/A
Interim Dividend	N/A	N/A
Record date for determining entitlements to the dividends (if any)	N/A	

Brief explanation of any of the figures reported above necessary to enable the figures to be understood: N/A

2. Key ratios

	Current Period	**Previous corresponding period**
Basic earnings per ordinary security (cents per share)	(3.04) cents	N/A
Diluted earnings per ordinary security (cents per share)	(3.36) cents	N/A
Net tangible asset backing per ordinary security (cents per share)	0.71 cent	N/A

3. Control Gained Over Entities Having Material Effect

Name of entity (or group of entities)	Paradigm Health Sciences Pty Ltd
Date control gained	05 June 2014
Profit / (loss) from ordinary activities after tax of the controlled entity since the date in the current period on which control was acquired.	6,880
Profit / (loss) from ordinary activities after tax of the controlled entity (or group of entities) for the whole of the previous corresponding period.	6,880

4. Audit/Review Status

This report is based on accounts to which one of the following applies: (Tick one)			
The accounts have been audited		The accounts are in the process of being audited	✓
If the accounts are subject to audit dispute or qualification, a description of the dispute or qualification: N/A			

5. Attachments Forming Part of Appendix 4E

Attachment	**Details**
1	Consolidated Statement of Comprehensive Income
2	Consolidated Statement of Financial Position
3	Consolidated Statement of Changes in Equity
4	Consolidated Statement of Cash Flows
5	Events occurring after the reporting period

ATTACHMENTS

Paradigm Biopharmaceuticals Limited and Controlled Entities
A.B.N 94 169 346 963
Consolidated Statement of Comprehensive Income
For the period from 1 July 2014 to 30 June 2015

	Period from 1-July-14 to 30-Jun-15 $	Period from Incorporation 2-May-14 to 30-Jun-14 $
Other Income	7,331	-
Research & Development	(157,710)	-
Employee Expenses	(703,949)	-
General and Administration expenses	(226,777)	(38,573)
Loss before income tax	**(1,081,105)**	**(38,573)**
Income tax expense / (benefit)	-	-
Loss for the year	**(1,081,105)**	**(38,573)**
Other comprehensive income	**-**	**-**
Total comprehensive income attributable to members of the consolidated entity	**(1,081,105)**	**(38,573)**

Paradigm Biopharmaceuticals Limited and Controlled Entities
A.B.N 94 169 346 963
Consolidated Statement of Financial Position as at 30 June 2015

	Notes	30-Jun-15 $	30-Jun-14 $
ASSETS			
Current assets			
Cash and cash equivalents		124,857	7,773
Trade and other receivables		15,741	19,950
Prepaid Capital Raising Costs		697,527	100,157
Total current assets		**838,125**	**127,879**
Non-current assets			
Intangible assets		356,288	88,921
Total non-current assets		**356,288**	**88,921**
Total assets		**1,194,413**	**216,800**
LIABILITIES			
Current liabilities			
Trade and other payables		585,287	368,665
Total current liabilities		**585,287**	**368,665**
Net assets		**609,126**	**(151,865)**
EQUITY			
Issued capital		1,577,497	1
Share Options reserve		264,600	-
Accumulated losses		(1,232,972)	(151,866)
Total equity		**609,126**	**(151,865)**

Paradigm Biopharmaceuticals Limited and Controlled Entities
A.B.N 94 169 346 963
Consolidated Statement of Changes in Equity
For the period from 1 July 2014 to 30 June 2015

	Issued Capital $	Share Option Reserve $	Accumulated Losses $	Total $
Balance at 2 May 2014	-	-	-	-
Accumulated losses of Paradigm Heath Sciences Pty Ltd at 2 May 2014	-	-	(113,293)	(113,293)
Loss for the period	-	-	(38,573)	(38,573)
Shares issued	1	-	-	1
Balance at 30 June 2014	**1**	**-**	**(151,866)**	**(151,865)**
Loss for the period	-	-	(1,081,105)	(1,081,105)
Shares issued	1,835,000	-	-	1,835,000
Costs in relation to shares issued	(257,504)	-	-	(257,504)
Fair value of shares issued to eligible employees under the plan	-	264,600		264,600
Balance at 30 June 2015	**1,577,497**	**264,600**	**(1,232,971)**	**609,126**

Paradigm Biopharmaceuticals Limited and Controlled Entities
A.B.N 94 169 346 963
Consolidated Statement of Cash Flows
For the period from 1 July 2014 to 30 June 2015

	Period from 1-July-14 to 30-Jun-15 $	Period from Incorporation 2-May-14 to 30-Jun-14 $
Cash flows from operating activities		
Payments to suppliers and employees	(1,210,616)	(102,953)
Interest received	7,331	-
Net cash outflow from operating activities	**(1,203,285)**	**(102,953)**
Cash flows from investing activities		
Payments for intangible assets	(237,977)	(85,058)
Net cash outflow from investing activities	**(237,977)**	**(85,058)**
Cash flows from financing activities		
Receipts from issue of preference shares (net of the payment of costs)	1,582,345	1
Net movement in related party loans	(24,000)	195,783
Net cash inflow from financing activities	**1,558,345**	**195,784**
Net increase in cash and cash equivalents	**117,084**	**7,773**
Cash at the beginning of the financial period	**7,773**	**-**
Cash at the end of the financial period	**124,857**	**7,773**

Paradigm Biopharmaceuticals Limited and Controlled Entities
A.B.N 94 169 346 963
Notes to the Financial Statements
For the period from 1 July 2014 to 30 June 2015

1. Events occurring after the reporting period

On the 5 August 2015, Paradigm completed its Asset Purchase Agreement with Glycan Biosciences LLC with the final payment of $410,228 (USD300,000).

On the 7 August 2015, having obtained conditional approval from the ASX for the admission of Paradigm to the ASX Official List and having raised $8,000,000 as part of its Initial Public Offer, Paradigm completed the acquisition of Xosoma Pty Ltd.

Paradigm now owns 100% of Xosoma Pty Ltd and the Xosoma vendors have received 19,495,238 Paradigm shares.

On the 7 August 2015, the Series 1 Preference Shareholders holding 1,235,000 Preference Shares converted to 7,057,143 Ordinary Shares.

On the 7 August 2015, the Series 2 Preference Shareholders holding 600,000 Preference Shares converted to 2,637,363 Ordinary Shares.

On the 19 August 2015, having raised the maximum subscription of $8,000,000 as part of its Initial Public Offer, Paradigm shares were quoted on the Official List of the ASX.

Other than the matters noted above, no other matters or circumstances have arisen since balance date which have impacted or are likely to impact the Consolidated Entity's operations, results and state of affairs in future financial years.